Science AdvancesCancer BiologyPeer-reviewed journal article
An EYA3/NF-κB/CCL2 signaling axis suppresses cytotoxic NK cells in the pre-metastatic niche to promote triple negative breast cancer metastasis
Sheera R. RosenbaumiD, Connor J. HughesiD, Kaiah M. FieldsiD, Stephen Connor PurdyiD, Annika L. GustafsoniD, Arthur R. WoliniD, Drake HamptoniD, Natasha Shrivastava, Nicholas Turner, Etienne P. DanisiD, Christopher C. EbmeieriD, Nicole S. SpoelstraiD, Jennifer K. RicheriD, Paul JedlickaiD, James C. CostelloiD, Rui ZhaoiD, Heide L. FordiD
Abstract
Patients with Triple Negative Breast Cancer (TNBC) exhibit high rates of metastases and poor prognoses. The Eyes absent (EYA) family of proteins are developmental transcriptional cofactors/phosphatases that are re-expressed and/or upregulated in numerous cancers. Herein, we demonstrate that EYA3 correlates with decreased survival in breast cancer, and that it strongly, and specifically, regulates metastasis via a novel mechanism that involves NF-kB signaling and an altered innate immune profile at the pre-metastatic niche (PMN). Remarkably, restoration of NF-kB signaling downstream of Eya3 knockdown (KD) restores metastasis without restoring primary tumor growth, isolating EYA3/NF-kB effects to the metastatic site. We show that secreted CCL2, regulated downstream of EYA3/NF-kB, specifically decreases cytotoxic NK cells in the PMN and that re-expression of Ccl2 in Eya3-KD cells is sufficient to rescue activation/levels of cytotoxic NK cells in vitro and at the PMN, where EYA3-mediated decreases in cytotoxic NK cells are required for metastatic outgrowth. Importantly, analysis of public breast cancer datasets uncovers a significant correlation of EYA3 with NF-kB/CCL2, underscoring the relevance of EYA3/NF-kB/CCL2 to human disease. Our findings suggest that inhibition of EYA3 could be a powerful means to re-activate the innate immune response at the PMN, inhibiting TNBC metastasis. SignificanceEYA3 promotes metastasis of TNBC cells by promoting NF-kB-mediated CCL2 expression and inhibiting cytotoxic NK cells at the pre-metastatic niche, highlighting a potential therapeutic target in this subset of breast cancer.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- research focus: cancer & tumor microenvironment
- approach: experimental assay
- approach: statistical model
- Citations
- 14
- FWCI
- 3.36
- Field percentile
- top 6%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genetic and Pharmacologic Targeting of Eya3 in Macrophages Drives Anti-Tumor Immunity in Triple-Negative Breast Cancer
Kaiah M. Fields, Gabriela Terue Rizzo Kodama, … Heide L. Ford·bioRxiv·Oct 22, 2026
- Whole transcriptome analysis reveals ELK3 as a key driver of metastasis through regulation of 3D migration and stemness in triple-negative breast cancer cells
Daniel Cruceriu, Loredana Bălăcescu, … Ovidiu Bălăcescu·bioRxiv·Jul 22, 2026
- ERK3/MAPK6 promotes triple-negative breast cancer progression through collective migration and EMT plasticity
Sofia Morazzo, Soraia Fernandes, … Giancarlo Forte·Frontiers in OncologyPeer-reviewed·Aug 27, 2025
- TRAIL-induced cytokine production via NFKB2 pathway promotes neutrophil chemotaxis and immune suppression in triple negative breast cancers
Manjari Kundu, Yoshimi Endo Greer, … Stanley Lipkowitz·Cancer LettersPeer-reviewed·Apr 6, 2025
- Inhibition of EMT driver PTK6 enhances anti-tumor immune responses against triple-negative breast cancer
Ibuki Harada, Criseyda Martinez, … Hanna Yoko Irie·bioRxiv·Jan 11, 2025
- A selective inhibitor of oncogenic JNK signalling perturbs metastatic outgrowth of triple-negative breast cancer through metabolic blockade
Sharissa L. Latham, Yolande E. I. O’Donnell, … David R. Croucher·bioRxiv·Apr 16, 2025